Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Sunitinib
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms OCLURANDOM
- 11 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTriasl.gov record.
- 05 Sep 2014 New trial record